RBC Capital maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $665.00 (from $570.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Regeneron (REGN) PT Raised to $659 at Brean CapitalAugust 4, 2015 3:47 PM Regeneron (REGN) PT Raised to $664 at Leerink Partners; Reacceleration in EyleaAugust 4, 2015 3:45 PM Regeneron Pharma's (REGN) Price Target Raised to $720 at Deutsche BankAugust 4, 2015 1:19 PM Regeneron (REGN) Tops Q2 EPS by 12cAugust 4, 2015 6:34 AM Regeneron Reports Second Quarter 2015 Financial and Operating ResultsAugust 4, 2015 6:30 AM